Fatty Liver Disease MASLD (NAFLD): The Most Common Liver Disease, Reversible Early, and What Large Trials Do Not Support

Your doctor says your liver has fat buildup, and you are confused because you barely drink. So why did this happen? The answer is in the disease’s new name, which puts the real cause right up front.

The good news to know first is that this disease is reversible in its early stage. The liver is an organ that repairs itself well, if you address the root cause in time.

MASLD (metabolic dysfunction-associated steatotic liver disease) is fat accumulation in the liver that comes with metabolic abnormalities such as insulin resistance, abdominal fat, diabetes, and high blood pressure, and is not mainly caused by alcohol.

For some aspects of this disease, the evidence is strong and actionable. For others, the common belief is not supported by large trials. This article separates what is trustworthy from what still needs caution.

A Three-Line Summary

1. MASLD affects roughly one in three adults worldwide and is tightly linked to insulin resistance and abdominal fat, not to alcohol.
2. Losing 7 to 10 percent of body weight, a Mediterranean diet, and both aerobic and weight training are the foundation that can genuinely reverse the disease in its early stage.
3. New drugs resmetirom (2024) and semaglutide (2025) help the MASH fibrosis stage, but vitamin E and pioglitazone do not reverse fibrosis, and liver cancer can occur even without cirrhosis.

Why the Name Changed From NAFLD to MASLD

In 2023 the AASLD and EASL renamed this disease from NAFLD (non-alcoholic fatty liver disease) to MASLD through a Delphi consensus published in Hepatology (Rinella et al. 2023, PMID 37363821).

The old name, NAFLD, was defined by “not drinking alcohol,” which only said what the disease is not, and did not state the real cause.

The new name, MASLD, puts the real cause into the name itself: metabolic dysfunction. Diagnosis therefore looks at insulin resistance, abdominal fat, diabetes, and high blood pressure, not just at whether you drink.

Diagnosing MASLD requires liver fat (steatosis) plus at least one of these five cardiometabolic criteria.

1. BMI of 25 or above (23 or above for Asians), or waist circumference over 94 cm in men and over 80 cm in women
2. Fasting glucose of 100 mg/dL or above, or HbA1c of 5.7 percent or above, or type 2 diabetes
3. Blood pressure of 130/85 or above, or taking blood pressure medication
4. Triglycerides of 150 mg/dL or above, or taking lipid-lowering medication
5. HDL of 40 mg/dL or below in men, and 50 mg/dL or below in women

There is another group the old name did not cover: people who have MASLD but drink more heavily (women 140 to 350 grams per week, men 210 to 420 grams per week). They are classified as MetALD (metabolic and alcohol-related liver disease), an overlap zone between metabolism and alcohol.

How Common Is It, and How Does It Usually End

MASLD affects roughly one in three adults. The central estimate from recent meta-analyses is about 30 percent, and in Asia about 28 to 32 percent. The often-cited figure of 38.2 percent is the high end of the most recent range, so “about one in three” is the safest framing.

For Thai people specifically, prevalence in the general population is about 19 to 23 percent, rising to 35 to 44 percent in those with diabetes or central obesity.

The numbers look alarming, but for most people the disease course does not end badly.

Stage	Features	Proportion and time
Simple steatosis	Liver fat only, no inflammation, no fibrosis	Reversible
Progression to MASH	Hepatocyte ballooning, inflammation, and fibrosis	About 12 to 40 percent over 8 to 13 years
Progression to cirrhosis	Scarred liver	Only 3 to 5 percent, usually over more than 20 years

Most people with simple steatosis do not progress to cirrhosis if the root cause is managed.

How to Check Whether the Liver Is Starting to Scar

The usual approach is to start with an ultrasound to see whether there is liver fat, then assess fibrosis risk with FibroScan (transient elastography) and the FIB-4 score, which is calculated from age, liver enzymes, and platelet count.

Values worth remembering for FIB-4:

• FIB-4 above 2.67 indicates advanced fibrosis and warrants referral for in-depth assessment
• FIB-4 between 1.3 and 2.67 is intermediate and needs further assessment, such as FibroScan
• FIB-4 below 1.3 means low risk of advanced fibrosis

The 2024 AASLD and EASL guidance recommends targeted screening in high-risk groups, such as people with type 2 diabetes, central obesity with metabolic risk factors, or chronically elevated liver enzymes. The decision to test and how to interpret results should be made with your doctor.

Weight Loss Reverses the Disease in Steps

Weight loss is the most powerful medicine in the early stage, and it works in steps. The more you lose, the deeper the liver recovers.

• Losing 5 percent or more reduces liver fat (hepatic steatosis)
• Losing 7 percent or more improves inflammation and cell death in the liver (necroinflammation)
• Losing 10 percent or more improves or stabilizes fibrosis

These figures come from Vilar-Gomez 2015 (PMID 25865049), which used liver biopsies in 261 patients. Those who lost 10 percent or more had NASH resolution in 90 percent of cases and fibrosis regression in 45 percent. A target of 7 to 10 percent is therefore the range research shows is most worthwhile, because it reaches the level where the liver begins to repair fibrosis.

Diet and Exercise With Evidence

A Mediterranean diet, emphasizing vegetables, fruit, fish, olive oil, and whole grains, improves liver fat, insulin sensitivity, and the lipid profile.

On the exercise side, both aerobic and resistance training (weight training) reduce liver fat and improve insulin resistance about equally, when done at similar frequency and duration.

A resistance training formula used in research:

• Whole-body, multi-muscle movements, 8 to 10 exercises
• Loads at 60 to 80 percent of one-repetition maximum (1RM is the heaviest weight you can lift once)
• At least 3 times per week, continued for at least 12 weeks

Another piece of good news is that exercise works even without weight loss. Moderate aerobic activity of 150 to 240 minutes per week lowers liver fat by about 2 to 4 percent without any weight loss, which means moving your body has value in itself.

Coffee is also worth remembering. In people who already have NAFLD, coffee is associated with less fibrosis (OR 0.67, 95 percent confidence interval 0.55 to 0.80), most clearly above 3 cups per day, though it is not clear whether it prevents the disease in the general population.

Sugar-sweetened beverages and fructose (SSB) raise the risk in a stepwise way: low, medium, and high intake raise NAFLD risk by about 14, 26, and 53 percent respectively, through hepatic de novo lipogenesis, the making of new fat in the liver.

New Drugs Resmetirom and Semaglutide

Until recently, MASH with fibrosis had no specific drug, but in the past two years two have passed FDA review.

Resmetirom is a thyroid hormone receptor-beta agonist, granted FDA accelerated approval under the brand name Rezdiffra on 14 March 2024, for MASH with F2 to F3 fibrosis and without cirrhosis. In the MAESTRO-NASH trial (PMID 38324483), the treated group had MASH resolution without worsening fibrosis in about 25.9 to 29.9 percent, compared with 9.7 percent in the control group.

Semaglutide is a GLP-1 receptor agonist, granted FDA accelerated approval in 2025 for noncirrhotic MASH with moderate to advanced fibrosis. In the Phase 3 ESSENCE trial (PMID 40305708), an interim result at week 72, the treated group had MASH resolution in 62.9 percent compared with 34.3 percent on placebo, and fibrosis improvement in 36.8 percent compared with 22.4 percent.

A point to remember on order: resmetirom (March 2024) came before semaglutide (2025), so semaglutide is the first GLP-1 approved for MASH but not the first drug overall. Both are accelerated approvals based on surrogate endpoints, so long-term outcomes are still pending, and starting these drugs should be under the care of a specialist.

Liver Cancer Can Occur Even Without Cirrhosis

We usually assume liver cancer (HCC) follows cirrhosis, but in MASLD that is not always the case.

About 35 to 50 percent of HCC patients who have MASLD develop it without cirrhosis.

More concerning is how it is detected. In the group without cirrhosis, about 72 percent of cancers are found incidentally rather than through systematic screening, compared with 60 percent in the group with cirrhosis. That means current surveillance still misses many patients without cirrhosis. Risk factors to watch are male sex, age over 65, diabetes, high blood pressure, abnormal blood lipids, and low platelet count.

Points to Watch: Beliefs the Evidence Does Not Support, or Where It Is Still Thin

“Vitamin E reverses fibrosis”

In the PIVENS trial, vitamin E at 800 IU per day improved steatosis, inflammation, and hepatocyte ballooning, but did not improve fibrosis, and only about 43 percent of people responded. The benefit is therefore limited to NASH features, not the reversal of fibrosis (PIVENS, DOI 10.1056/NEJMoa0907929).

“Pioglitazone is a recommended targeted drug for MASH”

The EASL-EASD-EASO 2024 guidance states that pioglitazone cannot yet be recommended as a targeted MASH drug, because it lacks large Phase III evidence for reversing fibrosis. Although some studies suggest benefit, the matter remains debated among experts.

“Omega-3 lowers liver fat directly”

Omega-3 PUFAs improve triglycerides, cholesterol, HDL, and BMI, but many studies find no effect on AST, ALT, or liver fat measured by MRS or MRI-PDFF. The benefit is on the metabolic side, not direct liver fat reduction.

“Thin people do not get fatty liver”

Lean MASLD can occur in people with normal BMI, and long-term outcomes can be worse than in thin people without MASLD. BMI alone does not tell you the risk; metabolic risk factors matter more than the BMI category.

“Milk thistle or silymarin and liver detox treat the disease”

A randomized trial in biopsy-proven NASH found that silymarin did not improve the NAFLD activity score over placebo, and a meta-analysis concluded that more confirmation is needed; it is not a standalone treatment. The term “liver detox” has no supporting evidence.

A Small Step You Can Take

If your waist is above the threshold, or you have diabetes, high blood pressure, or abnormal blood lipids, talking with your doctor about testing for liver fat and assessing fibrosis risk is a better start than guessing. In its early stage this disease is reversible, and the most powerful medicine is 7 to 10 percent weight loss, a Mediterranean diet, and regular movement. New drugs are reserved for the MASH fibrosis stage under a doctor’s care. This is caring for your liver with understanding, not fear that sends you down the wrong path.

This article is for understanding, not medical advice, and you should consult a doctor before deciding to test or treat.